Stockscreener 앱 받기
79.67
0.71%
0.56
시간 외 거래:
79.67
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Stock Traders Buy High Volume of Ionis Pharmaceuticals Call Options (NASDAQ:IONS) - MarketBeat
Diversified Trust Co Invests $1.02 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Death Cross: Can Ionis Pharmaceuticals Inc stock continue upward trendMarket Movers & Reliable Breakout Forecasts - moha.gov.vn
Revenues Not Telling The Story For Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - 富途牛牛
162,800 Shares in Ionis Pharmaceuticals, Inc. $IONS Bought by Capricorn Fund Managers Ltd - MarketBeat
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Ionis Pharmaceuticals Sees Rapid Rise On RNA Drug Progress - Finimize
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Finviz
How Ionis Pharmaceuticals Inc. stock reacts to job market dataJuly 2025 Review & High Accuracy Trade Alerts - ulpravda.ru
Discipline and Rules-Based Execution in IONS Response - news.stocktradersdaily.com
Will Ionis Pharmaceuticals Inc. stock outperform international peers2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Assenagon Asset Management S.A. Boosts Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
cathie wood’s ARK stock trades highlight ionis pharma sale By Investing.com - Investing.com Canada
cathie wood’s ARK stock trades highlight ionis pharma sale - Investing.com
Dip Buying: How Ionis Pharmaceuticals Inc. stock reacts to job market dataFed Meeting & Weekly Top Performers Watchlists - Улправда
How Ionis Pharmaceuticals Inc. stock compares to industry benchmarksJuly 2025 Sentiment & Reliable Breakout Stock Forecasts - DonanımHaber
Will Ionis Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Snapshot & Safe Swing Trade Setups - DonanımHaber
Can Ionis Pharmaceuticals Inc. stock continue upward trend2025 Growth vs Value & Daily Chart Pattern Signal Reports - DonanımHaber
Is Ionis Pharmaceuticals Inc. stock a safe investment in uncertain marketsForecast Cut & AI Optimized Trading Strategy Guides - Улправда
Ionis Pharmaceuticals Inc (HAM:ISI) Competitors 2025 - GuruFocus
Ionis Pharmaceuticals Inc Stock Operating Data - GuruFocus
Why Ionis Pharmaceuticals Inc. stock is a value investor pickIPO Watch & Proven Capital Preservation Methods - Улправда
Why retail investors favor Ionis Pharmaceuticals Inc. stockWeekly Risk Summary & Safe Entry Point Identification - Улправда
RBC Capital Maintains Ionis Pharmaceuticals (IONS) Outperform Recommendation - Nasdaq
How reliable is Ionis Pharmaceuticals Inc. (ISI) stock dividend growthStock Buyback Updates & Learn the Basics of Investing in 5 Days - Bollywood Helpline
RBC Capital Raises Price Target for Ionis Pharmaceuticals (IONS) to $95 | IONS Stock News - GuruFocus
RBC Raises Price Target on Ionis Pharmaceuticals to $95 From $82, Keeps Outperform Rating - marketscreener.com
Sicart Associates LLC Has $10.75 Million Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals stock price target raised to $95 from $82 at RBC Capital - Investing.com UK
EBITDA per share of Ionis Pharmaceuticals, Inc. – TRADEGATE:ISI - TradingView — Track All Markets
Ionis Pharmaceuticals (IONS): Leerink Partners Raises Price Targ - GuruFocus
Squarepoint Ops LLC Sells 170,978 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercial - pharmiweb.com
Ionis to hold third quarter 2023 financial results webcast - GuruFocus
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Marex Group plc Buys New Shares in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Hudson Bay Capital Management LP Has $29.63 Million Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Levels Update: Can Ionis Pharmaceuticals Inc stock sustain market leadershipJuly 2025 Review & Real-Time Volume Trigger Notifications - moha.gov.vn
Adage Capital Partners GP L.L.C. Raises Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN
B of A Securities Maintains Ionis Pharmaceuticals (IONS) Buy Recommendation - Nasdaq
Ionis Pharmaceuticals (IONS) Price Target Raised by B of A Securities | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $97.00 - MarketBeat
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials - openPR.com
Ionis Pharmaceuticals, Inc. (IONS) Presents at The 67th American Society of Hematology (ASH) Annual MeetingSlideshow (NASDAQ:IONS) 2025-12-09 - Seeking Alpha
450,254 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Norges Bank - MarketBeat
Polycythemia Vera Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharm - Barchart.com
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
Can Ionis Pharmaceuticals Stock Hold Up When Markets Turn? - Trefis
Has Ionis Pharmaceuticals Run Too Far After 135% Surge and Bullish DCF Outlook? - Yahoo Finance
Ionis Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
How Twin FDA Breakthrough Therapy Wins Could Impact Ionis Pharmaceuticals (IONS) Investors - Sahm
Kennedy Capital Management LLC Has $5.22 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Hsbc Holdings PLC Purchases 33,461 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Capital Fund Management S.A. Sells 26,795 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) Director Sells $2,262,960.00 in Stock - MarketBeat
Rx Rundown: Bristol Myers Squibb, Retro Bio, Ionis Pharmaceuticals and more - Medical Marketing and Media
Is Ionis Pharmaceuticals Inc. (ISI) stock suitable for passive index fundsEarnings Growth Summary & Accurate Entry/Exit Alerts - Newser
What Does the Market Think About Ionis Pharmaceuticals Inc? - Benzinga
Is Ionis Pharmaceuticals Inc. (ISI) stock undervalued after correctionJuly 2025 Catalysts & Weekly High Momentum Picks - Newser
0.57%
자본화:
|
볼륨(24시간):